Scribe Therapeutics
Scribe Therapeutics is a clinical-stage biotechnology company founded in 2018 and headquartered in Alameda, California, engineering CRISPR-based genetic medicines through its proprietary "CRISPR by Design" platform. Co-founded by molecular engineers Benjamin Oakes, Brett Staahl, and David Savage alo
Scribe Therapeutics is an API provider whose private shares are listed on 2 secondary markets: Forge Global, Nasdaq Private Market.
Where It Trades
Listing data is compiled from the public marketplace pages of Forge Global, Hiive, EquityZen, Nasdaq Private Market, and Augment. A listing indicates that a venue has published a page for this company — it is not an offer, a quote, or investment advice, and APIs.io has no affiliation with any venue.
Work with this as data
Every listing here is available over the APIs.io API and to AI agents over MCP. Secondary Market is not yet its own endpoint on the v1 API. Reach it through catalog search and the tag graph, or the MCP server.